|
HRMY | Harmony Biosciences Holdings, Inc. |
|
|
HRMY | Harmony Biosciences Holdings, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.41 |
| Leverage | 30.88% |
| Market Cap | $ 2.1B |
| PE | 11.11 |
| Dividend Yield | 0.00% |
| Profit | $ 185.1m |
| Margin | 22.50% |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.